- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07505069
Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors
March 26, 2026 updated by: Nanolattix Biotechnology Co., Ltd.
RT01-89Zr is a TF-targeting radiopharmaceutical diagnostic agent.
This trial aims to evaluate the safety, biodistribution, dosimetry, and imaging characteristics of RT01-89Zr as a PET/CT tracer in patients with malignant solid tumors that highly express the TF target.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jingchun Yu
- Phone Number: 0510-68089404
- Email: ycjwxd1978@jiangnan.edu.cn
Study Locations
-
-
Jiangsu
-
Wuxi, Jiangsu, China, 214122
- Recruiting
- Affiliated Hospital of Jiangnan University
-
Contact:
- Jingchun Yu
- Phone Number: 0510-68089404
- Email: kjc68088861@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients of either gender, ages 18-75 (including 18 and 75);
- ECOG Performance Status: 0 or 1;
- Confirmed as a solid tumor by histopathology or cytology;
- At least one primary or metastatic lesion confirmed by conventional imaging;
- During the screening period, tumor tissue samples (either archived previously or freshly biopsied) can be provided, with positive target expression of more than 1%;
- Voluntarily participate in this study and sign a written informed consent form, agree to comply with the research procedures, and cooperate throughout the entire research process;
- Women of childbearing potential must have a negative pregnancy test result. If the patient is of childbearing potential, she must agree to abstain from sexual activity or use highly effective contraception from the time of signing the informed consent until 3 months after the administration of the investigational drug;
Exclusion Criteria:
- Patients who are unable to complete a PET/CT scan (including those who cannot lie flat, have claustrophobia, or have fear of radiation, etc.);
- Those who have received radiopharmaceuticals before administration and whose discontinuation duration does not exceed 5 half-lives;
- Participants who have participated in other clinical trials within the past 3 months (except for clinical trials of investigational drugs discontinued for more than 5 half-lives, and assessed by the investigator as having no impact on endpoint evaluation and participant safety), or who plan to participate during the trial;
- Acute systemic diseases and electrolyte disorders;
- Patients known to be allergic to the RT01 contrast agent or synthetic excipients;
- Researchers believe that patients with poor adherence;
- Patients who are pregnant or breastfeeding;
- Other factors that render the patient unsuitable for trial participation..
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: RT01-89Zr
|
Intravenous injection of RT01-89Zr with a dosage of 1-2 mCi
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety evaluation
Time Frame: Within 21 days after administration
|
The number and percentage of patients with adverse events/serious adverse events
|
Within 21 days after administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biological distribution
Time Frame: through study completion, an average of 3 months
|
Obtain the accumulation (%ID)of each organ of interest through RT01-89Zr PET/CT images
|
through study completion, an average of 3 months
|
|
Radiation Dosimetry
Time Frame: through study completion, an average of 3 months
|
Calculate the radiation-absorbed dose of each organ and lesion and the whole-body effective dose using the MIRD method
|
through study completion, an average of 3 months
|
|
Visual Analysis
Time Frame: through study completion, an average of 3 months
|
Image visual score 0-3 (0 no obvious uptake, 1 slightly above background, 2 above background, 3 significantly above background)
|
through study completion, an average of 3 months
|
|
Semi-quantitative analysis
Time Frame: through study completion, an average of 3 months
|
Standard uptake values (SUVmax, SUVmean)
|
through study completion, an average of 3 months
|
|
Probe Targeting Performance Analysis
Time Frame: through study completion, an average of 3 months
|
The sensitivity (positive rate) of RT01-89Zr PET/CT in patients with solid tumors
|
through study completion, an average of 3 months
|
|
Biological distribution
Time Frame: through study completion, an average of 3 months
|
Retention time of each organ of interest through RT01-89Zr PET/CT images
|
through study completion, an average of 3 months
|
|
Biological distribution
Time Frame: through study completion, an average of 3 months
|
Standard uptake value(SUV) of each organ of interest through RT01-89Zr PET/CT images
|
through study completion, an average of 3 months
|
|
Semi-quantitative analysis
Time Frame: through study completion, an average of 3 months
|
Target-to-background ratio (TBR) (background can include mediastinum, general background, liver, muscle);
|
through study completion, an average of 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 29, 2026
Primary Completion (Estimated)
December 30, 2026
Study Completion (Estimated)
February 28, 2027
Study Registration Dates
First Submitted
March 10, 2026
First Submitted That Met QC Criteria
March 26, 2026
First Posted (Actual)
April 1, 2026
Study Record Updates
Last Update Posted (Actual)
April 1, 2026
Last Update Submitted That Met QC Criteria
March 26, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- QM-RT01-2551
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.